Klaviyo stock drops nearly 10% as 2026 opens — what KVYO investors watch next

Klaviyo stock drops nearly 10% as 2026 opens — what KVYO investors watch next

NEW YORK, Jan 3, 2026, 19:55 ET — Market closed

  • Klaviyo shares closed down 9.7% on Friday, underperforming several software peers.
  • U.S. Treasury yields rose as markets started 2026, a backdrop that often pressures high-growth software valuations. Reuters
  • The company’s next earnings report is estimated for Feb. 18. Nasdaq

Shares of Klaviyo (KVYO) closed down 9.7% on Friday at $29.32, marking a sharp slide on the first trading day of 2026.

The move matters now because investors began the new year with a fresh rate backdrop: U.S. Treasury yields climbed, and growth stocks lagged as traders recalibrated expectations for Federal Reserve policy and upcoming data. Reuters

Klaviyo’s drop also puts attention back on what the company says about 2026 demand and margins when it next reports results, with the earnings date currently estimated for Feb. 18. Nasdaq

U.S. stocks finished mixed on Friday, with the Dow and S&P 500 higher while the Nasdaq ended slightly lower, weighed by megacap tech. The benchmark 10-year yield rose to about 4.19%. Reuters

High-growth software names broadly weakened, though Klaviyo’s decline was steeper than several larger peers: HubSpot fell about 4.7% and Salesforce slid about 4.3% on the day, while Shopify dropped about 2.3%.

Trading conditions were also thin around the holiday, which can amplify intraday swings. “People not engaged normally,” said Jed Ellerbroek, a portfolio manager at Argent Capital. Reuters

Klaviyo traded between $29.15 and $32.46 on Friday and ended the session with about 4.93 million shares changing hands.

On the analyst side, Zacks Investment Research currently assigns Klaviyo a Rank #1 (“Strong Buy”), citing upward earnings estimate revisions in its model. Zacks Advisor Tools

The company sells a software platform that helps brands send and measure marketing messages across email, SMS text and push notifications. Zacks Advisor Tools

Investors have also been watching leadership changes: Chano Fernández joined co-founder Andrew Bialecki as co-chief executive officer effective Jan. 1, following a board appointment disclosed in an SEC filing. SEC

Before Monday’s open, attention will turn to the next wave of U.S. economic releases that traders see as key for the Fed’s path, after disruptions left some indicators delayed. Reuters

The next company waypoint is earnings, with Feb. 18 the current estimate from market calendars and Zacks data. Traders will be looking for any change in growth expectations and signs of progress on profitability. Nasdaq

Technically, investors will watch whether KVYO holds near Friday’s low around $29 and whether it can reclaim the low-$30s, after a session that spanned more than $3 a share. The stock’s 52-week range sits roughly between $23.44 and $49.55, according to Zacks data. Zacks Advisor Tools

Stock Market Today

  • EVTC valuation after 17% yearly decline: fair value $32.80 signals undervaluation
    January 4, 2026, 7:58 PM EST. Evertec (EVTC) has slid about 11% in 3 months and roughly 17% in the past year, with shares at $28.68 and a 1-year total return of -16.7%. A narrative fair value of $32.80 suggests the stock is undervalued. The case rests on ongoing modernization of proprietary platforms, including Sinqia integration and upgrades, and repricing of legacy contracts that could lift EBITDA and free cash flow into next year. The upside assumes smooth Brazil integrations and stable key customer contracts; currency swings or renegotiations could quickly dent growth. The analysis frames a growth-focused view, but risk factors in Latin America exposure and execution milestones remain. Investors can tailor scenarios, but the base case envisions a revenue ramp and margin expansion that could justify the $32.80 target.
Pony AI stock jumps nearly 11% after CLSA starts coverage; what traders watch next
Previous Story

Pony AI stock jumps nearly 11% after CLSA starts coverage; what traders watch next

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus
Next Story

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Go toTop